Greg Schuster is a corporate associate in the Boston office of Kirkland & Ellis LLP. Greg’s practice focuses on mergers and acquisitions for public and private companies primarily in the pharmaceutical, biotechnology and technology industries.
Experience
Representative Matters
Prior to joining Kirkland, Greg was involved in the following representative matters:
Chimerix in its $935 million sale to Jazz Pharmaceuticals
Evergreen Theragnostics in its sale to Lantheus for up to $1 billion
The special committee of the board of directors of EngageSmart in its $4 billion sale to Vista Equity Partners
Intercept Pharmaceuticals in its sale to Alfasigma for approximately $800 million
Iveric Bio in its $5.9 billion sale to Astellas
Adtalem Global Education in the $1 billion sale of its financial services segment to a consortium of Wendel Group and Colibri Group
Strongbridge Biopharma in its sale to Xeris Pharmaceuticals for $267 million
Pandion Therapeutics in its sale to Merck & Co. for $1.85 billion
Kelso & Company in the acquisition of Refresh Mental Health from Lindsay Goldberg
CerSci Therapeutics in its sale to ACADIA Pharmaceuticals for up to $939.5 million
Stemline Therapeutics in its sale to Menarini Group for up to $677 million
Gilead Sciences in its $4.9 billion acquisition of Forty Seven
ArQule in its sale to Merck for $2.7 billion
Achillion in its sale to Alexion for up to $1.225 billion
